‘Disruptor’ Mark Cuban Takes Aim At US Industry Barriers
Billionaire Entrepreneur Says Trust And Transparency Will Lift Reputation Of Generics
During a lively discussion at the AAM’s Access! conference in Orlando, billionaire entrepreneur Mark Cuban set out how he plans to use his Cost Plus Drugs company to disrupt the generics sector while also lifting its reputation by increasing trust and transparency among patients.
You may also be interested in...
AAM’s Baeder Takes A Focused Approach To Articulating Industry Priorities
Christine Baeder, Teva’s chief operating officer for US generics and biosimilars, was named chair of the AAM’s board in February. Speaking with Generics Bulletin, she sets out her priorities against the backdrop of a US generics industry that is now at an “inflection point” for sustainability.
Sandoz’s Saynor Reflects On Industry Challenges
In the third and final part of his exclusive interview with Generics Bulletin, Sandoz CEO Richard Saynor discusses global off-patent industry challenges including antibiotics shortages, PBM behavior in the US and the UK’s VPAS rebate mechanism.
AAM Names Teva’s Baeder Chair As It Kicks Off Annual Meeting
Christine Baeder has become chair of the AAM’s board, with the Teva executive welcomed to role as the US industry association kicked off its annual Access! conference in Orlando.